Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma

Qin Tang , Guanghui Hu , Ye Sang , Yulu Chen , Guangyan Wei , Meiyan Zhu , Mengke Chen , Shiyong Li , Rengyun Liu , Zhenwei Peng

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1703

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1703 DOI: 10.1002/ctm2.1703
RESEARCH ARTICLE

Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma

Author information +
History +
PDF

Abstract

TERT promoter mutation confers sensitivity to PLK1 inhibitors in HCC.

• The selective growth inhibition of TERT mutant HCC cells induced by PLK1 inhibitor was mediated by Smad3.

• Combined inhibition of PLK1 and Smad3 showed a cooperative anti-tumor effect in TERT mutant HCC cells.

Keywords

hepatocellular carcinoma / PLK1 / Smad3 / TERT promoter mutation

Cite this article

Download citation ▾
Qin Tang,Guanghui Hu,Ye Sang,Yulu Chen,Guangyan Wei,Meiyan Zhu,Mengke Chen,Shiyong Li,Rengyun Liu,Zhenwei Peng. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma. Clinical and Translational Medicine, 2024, 14(5): e1703 DOI:10.1002/ctm2.1703

登录浏览全文

4963

注册一个新账户 忘记密码

References

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

142

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/